Suppr超能文献

三氧化二砷和其他砷化合物抑制 NLRP1、NLRP3 和 NAIP5/NLRC4 炎性小体。

Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.

机构信息

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.

出版信息

J Immunol. 2014 Jan 15;192(2):763-70. doi: 10.4049/jimmunol.1301434. Epub 2013 Dec 13.

Abstract

Inflammasomes are large cytoplasmic multiprotein complexes that activate caspase-1 in response to diverse intracellular danger signals. Inflammasome components termed nucleotide-binding oligomerization domain-like receptor (NLR) proteins act as sensors for pathogen-associated molecular patterns, stress, or danger stimuli. We discovered that arsenicals, including arsenic trioxide and sodium arsenite, inhibited activation of the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes by their respective activating signals, anthrax lethal toxin, nigericin, and flagellin. These compounds prevented the autoproteolytic activation of caspase-1 and the processing and secretion of IL-1β from macrophages. Inhibition was independent of protein synthesis induction, proteasome-mediated protein breakdown, or kinase signaling pathways. Arsenic trioxide and sodium arsenite did not directly modify or inhibit the activity of preactivated recombinant caspase-1. Rather, they induced a cellular state inhibitory to both the autoproteolytic and substrate cleavage activities of caspase-1, which was reversed by the reactive oxygen species scavenger N-acetylcysteine but not by reducing agents or NO pathway inhibitors. Arsenicals provided protection against NLRP1-dependent anthrax lethal toxin-mediated cell death and prevented NLRP3-dependent neutrophil recruitment in a monosodium urate crystal inflammatory murine peritonitis model. These findings suggest a novel role in inhibition of the innate immune response for arsenical compounds that have been used as therapeutics for a few hundred years.

摘要

炎症小体是一种大型细胞质多蛋白复合物,可响应各种细胞内危险信号激活半胱氨酸蛋白酶-1。炎症小体的组成部分,称为核苷酸结合寡聚化结构域样受体 (NLR) 蛋白,作为病原体相关分子模式、应激或危险刺激的传感器。我们发现,砷剂,包括三氧化二砷和亚砷酸钠,通过其各自的激活信号(炭疽致死毒素、 Nigericin 和鞭毛蛋白)抑制 NLRP1、NLRP3 和 NAIP5/NLRC4 炎症小体的激活。这些化合物阻止了半胱氨酸蛋白酶-1 的自水解激活以及巨噬细胞中白细胞介素-1β 的加工和分泌。抑制作用不依赖于蛋白质合成诱导、蛋白酶体介导的蛋白质降解或激酶信号通路。三氧化二砷和亚砷酸钠不会直接修饰或抑制预先激活的重组半胱氨酸蛋白酶-1 的活性。相反,它们诱导一种细胞状态,抑制半胱氨酸蛋白酶-1 的自水解和底物切割活性,这种抑制状态可被活性氧清除剂 N-乙酰半胱氨酸逆转,但不能被还原剂或 NO 途径抑制剂逆转。砷剂可提供针对 NLRP1 依赖性炭疽致死毒素介导的细胞死亡的保护,并在单钠尿酸盐晶体炎症性小鼠腹膜炎模型中防止 NLRP3 依赖性中性粒细胞募集。这些发现表明,砷化合物在抑制先天免疫反应方面具有新的作用,这些化合物已经作为治疗药物使用了数百年。

相似文献

1
Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.
J Immunol. 2014 Jan 15;192(2):763-70. doi: 10.4049/jimmunol.1301434. Epub 2013 Dec 13.
2
The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes.
J Immunol. 2015 Mar 15;194(6):2776-85. doi: 10.4049/jimmunol.1401611. Epub 2015 Feb 13.
3
Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism.
J Leukoc Biol. 2016 Jan;99(1):189-99. doi: 10.1189/jlb.3A0415-155RR. Epub 2015 Aug 12.
4
Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.
Immunol Invest. 2023 Apr;52(3):364-397. doi: 10.1080/08820139.2023.2168554. Epub 2023 Feb 6.
5
Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function.
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17254-9. doi: 10.1073/pnas.1415756111. Epub 2014 Nov 17.
6
Novel role of PKR in inflammasome activation and HMGB1 release.
Nature. 2012 Aug 30;488(7413):670-4. doi: 10.1038/nature11290.
8
The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus.
Nature. 2011 Sep 14;477(7366):596-600. doi: 10.1038/nature10510.
9
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.
Nature. 2012 Oct 4;490(7418):107-11. doi: 10.1038/nature11351. Epub 2012 Aug 19.
10
Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity.
Nature. 2011 Aug 28;477(7366):592-5. doi: 10.1038/nature10394.

引用本文的文献

1
Neuro-inflammation Induced by Arsenic: An Insight into Mechanisms and Pathways Involved.
Biol Trace Elem Res. 2025 Jun 30. doi: 10.1007/s12011-025-04717-8.
3
Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.
Adv Sci (Weinh). 2025 Feb;12(6):e2406324. doi: 10.1002/advs.202406324. Epub 2025 Jan 3.
4
The role of TIGIT-CD226-PVR axis in mediating T cell exhaustion and apoptosis in NSCLC.
Apoptosis. 2025 Apr;30(3-4):784-804. doi: 10.1007/s10495-024-02052-2. Epub 2024 Dec 26.
5
Spatial nonstationarity and the role of environmental metal exposures on COVID-19 mortality in New Mexico.
Appl Geogr. 2024 Oct;171. doi: 10.1016/j.apgeog.2024.103400. Epub 2024 Aug 30.
6
NLRP inflammasomes in health and disease.
Mol Biomed. 2024 Apr 22;5(1):14. doi: 10.1186/s43556-024-00179-x.
7
8
Pyroptosis and pyroptosis-inducing cancer drugs.
Acta Pharmacol Sin. 2022 Oct;43(10):2462-2473. doi: 10.1038/s41401-022-00887-6. Epub 2022 Mar 14.
9
AS3MT facilitates NLRP3 inflammasome activation by mA modification during arsenic-induced hepatic insulin resistance.
Cell Biol Toxicol. 2023 Oct;39(5):2165-2181. doi: 10.1007/s10565-022-09703-7. Epub 2022 Feb 28.
10
Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models.
Molecules. 2021 Aug 18;26(16):4996. doi: 10.3390/molecules26164996.

本文引用的文献

1
Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model.
Biomed Res Int. 2013;2013:937936. doi: 10.1155/2013/937936. Epub 2013 Jan 16.
2
Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.
Blood. 2013 Apr 18;121(16):3185-94. doi: 10.1182/blood-2012-05-432104. Epub 2013 Feb 21.
3
Effects of arsenic trioxide (As(2)O(3)) on airway remodeling in a murine model of bronchial asthma.
Can J Physiol Pharmacol. 2012 Dec;90(12):1576-84. doi: 10.1139/y2012-127. Epub 2012 Nov 23.
4
Anthrax lethal factor cleaves mouse nlrp1b in both toxin-sensitive and toxin-resistant macrophages.
PLoS One. 2012;7(11):e49741. doi: 10.1371/journal.pone.0049741. Epub 2012 Nov 12.
5
Inflammasomes and their roles in health and disease.
Annu Rev Cell Dev Biol. 2012;28:137-61. doi: 10.1146/annurev-cellbio-101011-155745. Epub 2012 Sep 10.
6
Rapid induction of inflammatory lipid mediators by the inflammasome in vivo.
Nature. 2012 Oct 4;490(7418):107-11. doi: 10.1038/nature11351. Epub 2012 Aug 19.
7
Redox control of NLRP3 inflammasome activation in health and disease.
J Leukoc Biol. 2012 Nov;92(5):951-8. doi: 10.1189/jlb.0512265. Epub 2012 Aug 2.
8
Current status of inflammasome blockers as anti-inflammatory drugs.
Expert Opin Investig Drugs. 2012 Jul;21(7):995-1007. doi: 10.1517/13543784.2012.690032. Epub 2012 May 22.
9
Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome.
PLoS Pathog. 2012;8(3):e1002638. doi: 10.1371/journal.ppat.1002638. Epub 2012 Mar 29.
10
Inflammasomes in carcinogenesis and anticancer immune responses.
Nat Immunol. 2012 Mar 18;13(4):343-51. doi: 10.1038/ni.2224.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验